Categories
International & World

“Nobody knows“: Experts baffled by mystery illness in India

A patient is assisted by others to get down from an ambulance at the district government hospital in Eluru, Andhra Pradesh state, India, Tuesday, Dec.8, 2020. Health officials and experts are still baffled by a mysterious illness that has left over 500 people hospitalized and one person dead in this southern Indian state. (AP Photo)

 

NEW DELHI (AP) — Health officials and experts are still baffled by a mysterious illness that has left over 500 people hospitalized and one person dead in the southern Indian state of Andhra Pradesh.

The illness was first detected Saturday evening in Eluru, an ancient city famous for its hand-woven products. People started convulsing without any warning, said Geeta Prasadini, the director of public health.

Since then, symptoms ranging from nausea and anxiety to loss of consciousness have been reported in 546 patients admitted to hospitals. Many have recovered and returned home, while 148 are still being treated, said Dasari Nagarjuna, a government spokesperson.

Teams of experts have arrived at the city from India’s top scientific institutes. Different theories have been suggested and are being tested. The most recent hypothesis is contamination of food by pesticides.

“But nobody knows,” Prasadini admitted.

What is confounding experts is that there doesn’t seem to be any common link among the hundreds of people who have fallen sick. All of the patients have tested negative for COVID-19 and other viral diseases such as dengue, chikungunya or herpes. They aren’t related to each other. They don’t all live in the same area. They’re from different age groups, including about 70 children, but very few are elderly.

Initially, contaminated water was suspected. But the chief minister’s office confirmed that people who don’t use the municipal water supply have also fallen ill, and that initial tests of water samples didn’t reveal any harmful chemicals.

A 45-year-old man with the single name Sridhar was hospitalized with symptoms resembling epilepsy and died Sunday evening, doctors said. Prasadini said his autopsy didn’t shed any light on the cause of death.

The hypothesis currently being tested is that people ate vegetables tainted with pesticides made of organic compounds containing phosphorus. But this is an “assumption” based on the fact that such pesticides are commonly used in the area and not on any evidence, Prasadini said.

She said that experts were testing to see if pesticides had contaminated fish ponds or spilled over to vegetables.

Opposition leader N. Chandrababu Naidu demanded on Twitter an “impartial, full-fledged inquiry into the incident.”

Andhra Pradesh state is among those worst hit by COVID-19, with over 800,000 detected cases. The health system in the state, like the rest of India, has been frayed by the virus.

___

Associated Press writer Chonchui Ngashangva contributed to this report.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

 


— Associated Press

Categories
Healthcare

Scripps Research names Jin-Quan Yu to newly-endowed Bristol Myers Squibb Chair in Chemistry

PRINCETON, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)–$BMY #BMSBristol Myers Squibb (NYSE: BMY) and Scripps Research today announced that Bristol Myers Squibb has endowed a chair in chemistry at Scripps Research to advance scientific research critical to drug discovery.

Scripps Research has named Professor Jin-Quan Yu, PhD, a pioneering chemist whose research has paved the way to powerful new techniques used in fields ranging from drug discovery to materials science, to be the inaugural holder of the Bristol Myers Squibb Endowed Chair in Chemistry.

Bristol Myers Squibb and Scripps Research have had a long-standing relationship and we are proud to endow this chair to support transformative research with unrestricted funding,” said Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President and President, Research & Early Development, Bristol Myers Squibb. “We look forward to further groundbreaking chemistry to emerge from Scripps Research.”

Academic research serves as a wellspring for advancements in medicine,” said Peter Schultz, PhD, president and CEO of Scripps Research. “Looking at how a drug can progress from a discovery in our labs to an approved medicine for patients, it becomes clear that effective translation of academic discoveries to biopharma is essential for tackling the world’s health challenges.”

Schultz continued, “The new $3 million chair endowed by Bristol Myers Squibb can help to support the next generation of biomedical breakthroughs by providing sustained, unrestricted funding to support research programs. Jin-Quan’s creative insights and unconventional approach to organic synthesis have already transformed chemical processes used for developing new medicines and many other products that can impact people’s lives around the globe.”

Yu received his doctorate in chemistry from the University of Cambridge in 1999. He subsequently held positions as a postdoctoral fellow at Harvard University and as a junior faculty member at Cambridge and Brandeis University. He joined the faculty at Scripps Research in 2007, where he is the Frank and Bertha Hupp Professor of Chemistry.

In 2016, he was named a MacArthur Fellow for pioneering new methods in chemistry and enabling the development of versatile, novel and beneficial chemical compounds. His work was cited by the MacArthur Foundation as “breaking down barriers to the development of versatile compounds with enormous benefits to academic, industrial, and pharmaceutical research.”

Yu’s research team has published more than 200 papers in influential research journals and has forged collaborations with academic and industry leaders around the world. This includes a collaboration with Bristol Myers Squibb researchers to develop a valuable new technique, known as “ligand-accelerated non-directed C–H functionalization,” that has already found application in pharmaceutical chemistry and a wide range of other chemical industries.

I’m honored that Scripps Research has named me to be the Bristol Myers Squibb Endowed Chair in Chemistry,” says Yu. “This support ensures my team has the flexibility and resources to continue to pursue the most interesting and high-impact ideas.”

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

About Scripps Research

Scripps Research is ranked the most influential institution in the world for its impact on innovation. We expand basic knowledge in the biosciences, and use these fundamental advancements to develop profound innovations that improve wellbeing. Our researchers lead breakthrough studies that address the world’s most pressing health concerns. Our educational and training programs mold talented and committed students and postdocs into the next generation of leading scientists. We are accelerating the creation and delivery of medical breakthroughs to better human health around the globe.

corporatefinancial-news

Contacts

Bristol Myers Squibb
Media Inquiries:
Media@BMS.com

Scripps Research
Chris Emery

(301) 873-6952

Categories
For Edit

Uber giving self-driving car project to a start-up

Company executives once said having cars that can drive on their own would be a salvation for their business. But the effort turned into a legal and financial headache.

— NYT: Top Stories

Categories
For Edit

MSNBC names Rashida Jones as president

Ms. Jones, currently a senior vice president at the network, will become the highest-ranking Black woman in the TV news industry.

— NYT: Top Stories

Categories
For Edit

Years of research laid groundwork for speedy COVID-19 shots

FILE – In this Wednesday, Sept. 2, 2020 file photo, blood samples from volunteers participating in the last-stage testing of the COVID-19 vaccine by Moderna and the National Institutes wait to be processed in a lab at the University of Miami Miller School of Medicine in Miami. Creating vaccines and properly testing them less than a year after the world discovered a never-before-seen disease is incredible. But the two U.S. frontrunners are made in a way that promises speedier development may become the norm — especially if they prove to work long-term as well as they have in early testing. (AP Photo/Taimy Alvarez, File)

 

How could scientists race out COVID-19 vaccines so fast without cutting corners? A head start helped — over a decade of behind-the-scenes research that had new vaccine technology poised for a challenge just as the coronavirus erupted.

“The speed is a reflection of years of work that went before,” Dr. Anthony Fauci, the top U.S. infectious disease expert, told The Associated Press. “That’s what the public has to understand.”

Creating vaccines and having results from rigorous studies less than a year after the world discovered a never-before-seen disease is incredible, cutting years off normal development. But the two U.S. frontrunners are made in a way that promises speedier development may become the norm — especially if they prove to work long-term as well as early testing suggests.

“Abject giddiness,” is how Dr. C. Buddy Creech, a Vanderbilt University vaccine expert, described scientists’ reactions when separate studies showed the two candidates were about 95% effective.

“I think we enter into a golden age of vaccinology by having these types of new technologies,” Creech said at a briefing of the Infectious Diseases Society of America.

Both shots — one made by Pfizer and BioNTech, the other by Moderna and the National Institutes of Health — are so-called messenger RNA, or mRNA, vaccines, a brand-new technology. U.S. regulators are set to decide this month whether to allow emergency use, paving the way for rationed shots that will start with health workers and nursing home residents.

Billions in company and government funding certainly sped up vaccine development — and the unfortunately huge number of infections meant scientists didn’t have to wait long to learn the shots appeared to be working.

But long before COVID-19 was on the radar, the groundwork was laid in large part by two different streams of research, one at the NIH and the other at the University of Pennsylvania — and because scientists had learned a bit about other coronaviruses from prior SARS and MERS outbreaks.

“When the pandemic started, we were on a strong footing both in terms of the science” and experience handling mRNA, said Dr. Tal Zaks, chief medical officer of Massachusetts-based Moderna.

Traditionally, making vaccines required growing viruses or pieces of viruses — often in giant vats of cells or, like most flu shots, in chicken eggs — and then purifying them before next steps in brewing shots.

The mRNA approach is radically different. It starts with a snippet of genetic code that carries instructions for making proteins. Pick the right virus protein to target, and the body turns into a mini vaccine factory.

“Instead of growing up a virus in a 50,000-liter drum and inactivating it, we could deliver RNA and our bodies make the protein, which starts the immune response,” said Penn’s Dr. Drew Weissman.

Fifteen years ago, Weissman’s lab was trying to harness mRNA to make a variety of drugs and vaccines. But researchers found simply injecting the genetic code into animals caused harmful inflammation.

Weissman and a Penn colleague now at BioNTech, Katalin Kariko, figured out a tiny modification to a building block of lab-grown RNA that let it slip undetected past inflammation-triggering sentinels.

“They could essentially make a stealth RNA,” said Pfizer chief scientific officer Dr. Philip Dormitzer.

Other researchers added a fat coating, called lipid nanoparticles, that helped stealth RNA easily get inside cells and start production of the target protein.

Meanwhile at the NIH, Dr. Barney Graham’s team figured out the right target — how to use the aptly named “spike” protein that coats the coronavirus to properly prime the immune system.

The right design is critical. It turns out the surface proteins that let a variety of viruses latch onto human cells are shape-shifters — rearranging their form before and after they’ve fused into place. Brew a vaccine using the wrong shape and it won’t block infection.

“You could put the same molecule in one way and the same molecule in another way and get an entirely different response,” Fauci explained.

That was a discovery in 2013, when Graham, deputy director of NIH’s Vaccine Research Center, and colleague Jason McLellan were investigating a decades-old failed vaccine against RSV, a childhood respiratory illness.

They homed in on the right structure for an RSV protein and learned genetic tweaks that stabilized the protein in the correct shape for vaccine development. They went on to apply that lesson to other viruses, including researching a vaccine for MERS, a COVID-19 cousin, although it hadn’t gotten far when the pandemic began.

“That’s what put us in a position to do this rapidly,” Graham told the AP in February before the NIH’s vaccine was first tested in people. “Once you have that atomic-level detail, you can engineer the protein to be stable.”

Likewise, Germany’s BioNTech in 2018 had partnered with New York-based Pfizer to develop a more modern mRNA-based flu vaccine, giving both companies some early knowledge about how to handle the technology.

“This was all brewing. This didn’t come out of nowhere,” said Pfizer’s Dormitzer.

Last January, shortly after the new coronavirus was reported in China, BioNTech CEO Ugur Sahin switched gears and used the same method to create a COVID-19 vaccine.

Moderna also was using mRNA to develop vaccines against other germs including the mosquito-borne Zika virus — research showing promise but that wasn’t moving rapidly since the Zika outbreak had fizzled.

Then at the NIH, Graham woke up on Saturday Jan. 11 to see Chinese scientists had shared the genetic map of the new coronavirus. His team got to work on the right-shaped spike protein. Days later, they sent Moderna that recipe — and the vaccine race was on.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

 


— Associated Press

Categories
For Edit

Montepulciano d’Abruzzo: Highly popular but little known

It’s made of Italy’s second-most widely planted red grape, and the wines are priced to go. How come they don’t get more respect?

— NYT: Top Stories

Categories
For Edit

Senator Paul Sarbanes, author of Sarbanes-Oxley Act, dies at 87

Early in his career, Mr. Sarbanes introduced the first article of impeachment against Richard Nixon. Decades later, he wrote legislation in response to fraud scandals involving Enron and other companies.

— NYT: Top Stories

Categories
Healthcare

Bayer and Atara Biotherapeutics enter strategic collaboration for mesothelian-targeted CAR T-cell therapies for solid tumors

  • Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy
  • Bayer to enter CAR T-cell therapy space and expand oncology development pipeline with groundbreaking technology
  • Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy
  • Collaboration will focus on off-the-shelf T-cell immunotherapy ATA3271 for high mesothelin-expressing tumors
  • Atara to receive upfront payment of USD 60 million, and up to a total of USD 610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales
  • Atara to Host Conference Call on Monday, December 7 at 8:30 a.m. ET

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Atara is a pioneer in allogeneic T-cell immunotherapy with industry-leading allogeneic cell manufacturing processes and CAR T technologies. The licensed technology leverages Atara’s novel, proprietary Epstein-Barr Virus (EBV) T-cell platform combined with CAR T technologies targeting mesothelin to improve efficacy, persistence, safety, and durability of response.

“This transaction is a fundamental element of Bayer’s new Cell & Gene Therapy strategy. It strengthens our development portfolio through allogeneic cell therapies and consolidates our emerging leadership in the field,” said Wolfram Carius, Head of Bayer’s Cell & Gene Therapy Unit. “We look forward to collaborating with Atara to develop off-the-shelf CAR T-cell therapies for patients with difficult-to-treat cancers.”

“This exciting collaboration between Atara and Bayer will accelerate the development of mesothelin-targeted CAR T-cell therapies for multiple solid tumors and helps us advance the power of our allogeneic cell therapy platform to patients as quickly as possible,” said Pascal Touchon, President and CEO Atara. “Bayer’s proven track record in oncology global development and commercialization, and growing presence in cell and gene therapy, enhances Atara’s capabilities and complements our leading allogeneic T-cell platform.”

Under the terms of the agreement, Atara will lead IND (Investigational New Drug)-enabling studies and process development for ATA3271 while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization. Atara will continue to be responsible for the ongoing ATA2271 phase 1 study, for which an IND filing has been accepted and the clinical trial has been initiated. Atara will receive an upfront payment of USD 60 million and is eligible to receive payments from Bayer upon achievement of certain development, regulatory and commercialization milestones totaling USD 610 million, as well as tiered royalties up to low double-digit percentage of net sales.

As part of the transaction, Atara will also provide translational and clinical manufacturing services to be reimbursed by Bayer. In addition, for a limited period of time, Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates.

Atara Conference Call and Webcast Information

Atara will hold a conference call at 8:30 a.m. ET. Analysts and investors can participate in the conference call by dialing (888) 540-6216 for domestic callers and (734) 385-2715 for international callers, using the conference ID 3995182.

A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company’s website for 30 days following the live webcast.

About CAR-T cell therapy

T cells are a type of white blood cell that are critical in eliminating the body of abnormal and cancerous cells in healthy individuals. In cancer patients, these T cells frequently fail to either recognize or effectively engage cancer cells. CAR T-cell therapies involve engineering a human T cell to express a chimeric antigen receptor (CAR) that increases its ability to recognize cancer cells. These therapies use the immune system to fight cancer and have the potential to disrupt cancer care and potentially even provide a cure. Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors and is an attractive target for immune-based therapies, including CAR T therapy.

About Bayer’s new Cell & Gene Therapy (C&GT) Unit

In order to build up its presence in C&GT, Bayer is strengthening its internal C&GT capabilities. At the same time, the company is pursuing external strategic collaborations, technology acquisitions and licensing. The goal is to build robust platforms with broad application across different therapeutic areas. Strategically, Bayer focuses on selected areas of C&GT, such as stem cell therapies (with focus on induced pluripotent cells or iPSCs), gene augmentation, gene editing and allogeneic cell therapies in different indications. Leveraging external innovation together with the expertise of the teams at Bayer represents a key value-driver, especially in the highly dynamic and competitive field of C&GT. Bayer’s operating model for C&GT, where partners operate autonomously and are fully accountable to develop and progress their portfolio and technology, is essential for preserving their entrepreneurial culture and positions Bayer as a partner of choice. The role of Bayer’s C&GT Platform is to steer strategically, ensuring the different parts of the organization complement each other and combining the best in Biotech and Pharma know-how. As part of the Pharmaceuticals Division, the C&GT Platform will combine multiple backbone functions providing support across the entire value chain for the research and development of cell and gene therapies. This includes expertise in Research and Preclinical Development, CMC (Chemistry, Manufacturing and Controls), Clinical Development, Commercial, Strategy Implementation and Project Management. With a high level of flexibility, it will orchestrate operations from science to launch in order to generate and maintain a sustainable pipeline, with the goal to bring new products to market as fast as possible.

About Atara’s Mesothelin CAR-T Franchise

Two of Atara’s investigational CAR T immunotherapy programs, developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), target mesothelin—the autologous ATA2271 program and allogeneic ATA3271 program. Mesothelin is a tumor-specific antigen that is commonly expressed at high levels on the cell surface in many aggressive solid tumors including mesothelioma, non-small cell lung cancer, ovarian cancer and pancreatic cancer.

Both ATA2271 and ATA3271 are engineered for use in solid tumors as they incorporate Atara’s novel inclusion of both a PD-1 DNR construct to overcome checkpoint inhibition and a 1XX costimulatory domain on the CAR (chimeric antigen receptor) to enhance expansion and functional persistence of the CAR T cells. ATA3271, the allogeneic version of this CAR T, leverages Atara’s EBV T-cell platform and is currently in IND-enabling studies. ATA2271, the autologous version has enrolled the first patient in an open-label, single-arm Phase 1 clinical study in November 2020.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com

About Atara

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple chimeric antigen receptor T-cell (CAR T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

For additional information about the company, please visit atarabio.com and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Forward-Looking Statements

This press release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, forward-looking statements include statements regarding: the development, timing and progress of ATA2271 or ATA3271, the potential characteristics and benefits of ATA2271 or ATA3271, and the progress and results of, and prospects for, any collaboration involving ATA2271 or ATA3271, including the potential financial benefits to Atara thereof. Because such statements deal with future events and are based on Atara’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; the sufficiency of Atara’s cash resources and need for additional capital; and other risks and uncertainties affecting Atara’s and its development programs, including those discussed in Atara’s filings with the Securities and Exchange Commission (SEC), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

Contacts

Contact Bayer:

Daniel Childs, phone +973 437 0809
Email: daniel.childs@bayer.com

Rose Talarico, phone +973 856 1347
Email: rose.talarico@bayer.com

Find more information at www.pharma.bayer.com
Our online press service is just a click away: media.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/bayerpharma

Contact Atara:

Media
Kerry Beth Daly

Head, Corporate Communications

Atara Biotherapeutics

+1 516-982-9328

kdaly@atarabio.com

Investors
Eric Hyllengren

Vice President, Investor Relations & Finance

Atara Biotherapeutics

805-395-9669

ehyllengren@atarabio.com

Categories
For Edit

Inauguration planners rethink how to party in age of virus

FILE – In this Nov. 15, 2016, file photo, inaugural preparations continue on the West Front of Capitol Hill in Washington, looking at the National Mall and Washington Monument. Health care officials have been warning people for months to avoid parties. But what happens when it’s one of America’s biggest celebrations of them all _ the swearing in of a new president? (AP Photo/Susan Walsh, File)

 

WASHINGTON (AP) — Public health guidance to avoid big parties in the age of coronavirus is about to collide with what is typically one of America’s biggest celebrations of all: the swearing-in of a new president.

While lots of details are still to be worked out, this Jan. 20 is sure to be more subdued than prior inauguration days.

A giant parade down Pennsylvania Avenue? Not likely.

Fancy balls? They may morph into virtual events.

The traditional luncheon where lawmakers offer best wishes to the new president? It might not include food this year.

What about the swearing-in itself? The inaugural platform on the Capitol’s West Front is going up just like always, but it probably won’t be as crowded.

“I think you’re going to see something that’s closer to what the convention was like than a typical inauguration,” President-elect Joe Biden said Friday, referring to the all-virtual event that marked his nomination last summer. “First and foremost, in my objective, is to keep America safe but still allow people to celebrate — to celebrate and see one another celebrate.”

For their convention, Democrats pulled together a made-for-TV mashup of homemade videos, speeches from classrooms and living rooms, and music played from afar, narrated by celebrity hosts.

Biden’s swearing-in itself will not be virtual. But guests should be prepared to socially distance and wear a mask. Lawmakers are also considering requiring a COVID-19 test for anyone on the platform near the president-elect, said Paige Waltz, a spokesperson for the joint congressional committee charged with overseeing the event.

The VIP platform can hold 1,600 people. Lawmakers also generally distribute tickets for positions nearby. While no hard decisions have been made, the committee is looking at cutting the numbers on both accounts.

“My guess is there will still be a platform ceremony,” Biden said. “But I don’t know exactly how it’s all going to work out. The key is keeping people safe. I can’t do a super version of the president’s announcement in the Rose Garden.”

That was an apparent reference to President Donald Trump’s Rose Garden introduction of Supreme Court nominee Amy Coney Barrett, where hundreds of people crammed together, many without masks. It turned out to be a superspreader of the virus.

Biden’s play-it-safe approach to the coronavirus during his campaign offers clues about what to expect in terms of inaugural modifications.

He said Friday that a “gigantic inaugural parade down Pennsylvania Avenue” was unlikely, although a big reviewing stand is being constructed in front of the White House.

No decisions have been made on whether the official inaugural balls should go forward. Some advocacy groups already are going virtual with their galas, including the Human Rights Campaign, a gay rights organization.

“Our goal is to democratize the inauguration party experience by holding a virtual event integrating our 3 million-plus members and supporters into the day’s events and breaking the traditional bubble of a Washington insider experience,” said Lucas Acosta, a spokesperson for the group.

The celebrity component of this year’s celebration has yet to be determined, but one source close to the inauguration suggested looking for hints in the lineup of celebrities who campaigned for Biden, including Lady Gaga, John Legend and Jon Bon Jovi.

Work to build the inaugural platform at the Capitol and the White House reviewing stand began before the Nov. 3 election, as is traditional. New this year: Congressional planners have invited lawmakers to record video messages for the president-elect and vice president-elect that can be played on Jumbotrons before the swearing-in.

After the ceremony, the president and vice president have traditionally attended a luncheon in National Statuary Hall that includes speeches, gifts and toasts. The event began in 1953, when President Dwight Eisenhower, his wife, Mamie, and 50 guests dined on creamed chicken, baked ham and potato puffs in the Old Senate Chamber.

This year’s format and venue are up in the air. One congressional aide familiar with the planning said it’s likely that food will be out altogether. Rather, the event would revolve around the speeches lawmakers make wishing the new administration well.

Sen. Roy Blunt, R-Mo., who heads the congressional inaugural committee, has been careful not to refute Trump’s baseless claims that he won the election. But Waltz said the congressional inaugural committee staff nonetheless is ready to work with Biden’s Presidential Inaugural Committee.

That committee oversees inaugural events held away from the Capitol, including the parade and balls. Tony Allen, president of Delaware State University, serves as CEO.

“This year’s inauguration will look different amid the pandemic, but we will honor the American inaugural traditions and engage Americans across the country while keeping everybody healthy and safe,” Allen said.

Plans for protests are underway, too.

A few groups have submitted requests for protest permits with the National Park Service. The Answer Coalition, made up of antiwar and civil rights organizations, plans a demonstration demanding “urgent action to save the environment, end war and prioritize money to meet people’s needs.” Let America Hear Us Roar For Trump is seeking a permit to “support our President.”

As for Trump, it’s unclear whether he’ll show up for the inauguration. He recently told reporters: “I know the answer, but I just don’t want to say it yet.”

Biden, asked if Trump should attend, said it’s important for the United States to show that competing party leaders can stand together, shake hands and move on. “It is totally his decision, and it’s of no personal consequence to me. But I do think it is for the country,” he told CNN.

Even though plans are still taking shape, Biden’s inaugural committee is already raising money for such events as balls and concerts. The law allows unlimited contributions to the committee, but Biden will limit contributions from individuals to $500,000 and from corporations to $1 million. The committee won’t accept contributions from lobbyists or the fossil fuels industry.

That’s according to an inaugural official who spoke on condition of anonymity to discuss the work of the committee.

The contribution limits for Biden are far lower than those for Trump’s inaugural four years ago. He raised a record $107 million for his inauguration and accepted massive checks, including $5 million from Republican megadonor Sheldon Adelson.

The inauguration is normally an economic boon for the Washington region, with visitors typically required to book several days in a hotel and at premium rates to get a reservation. This year, there are more options than usual — a sign the inauguration is less of a draw.

“Given the pandemic, it’s good news that we’re hearing of some hotels being full already. But for the most part, there is still capacity in the city,” said Elliott L. Ferguson, president and CEO of Destination DC, the district’s marketing organization.

___

Associated Press writers Alexandra Jaffe and Brian Slodysko contributed to this report.

— Associated Press

Categories
For Edit

‘Existential peril’: Mass transit faces huge service cuts across U.S.

Reeling from the pandemic, transit agencies are grappling with drastic reductions in ridership and pleading for help from Washington.

— NYT: Top Stories